Global Nucleic Acid Testing Industry

Global Nucleic Acid Testing Industry

  • October 2019 •
  • 247 pages •
  • Report ID: 5817924 •
  • Format: PDF
Nucleic Acid Testing market worldwide is projected to grow by US$1.5 Billion, driven by a compounded growth of 7.2%. Nucleic Acid Test Kits, one of the segments analyzed and sized in this study, displays the potential to grow at over 7.3%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$3.2 Billion by the year 2025, Nucleic Acid Test Kits will bring in healthy gains adding significant momentum to global growth.

- Representing the developed world, the United States will maintain a 6.1% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$53.9 Million to the region’s size and clout in the next 5 to 6 years. Over US$46.1 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, Nucleic Acid Test Kits will reach a market size of US$171.2 Million by the close of the analysis period. As the world’s second largest economy and the new game changer in global markets, China exhibits the potential to grow at 10.6% over the next couple of years and add approximately US$427.6 Million in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

- Competitors identified in this market include among others, Abbott Molecular, Inc.; Beckman Coulter - Life Science Division; Becton, Dickinson and Company; Bio-Rad Laboratories, Inc.; F. Hoffmann-La Roche AG; Illumina, Inc.; Novartis International AG; Sequenom, Inc.; Siemens Healthineers; Tecan Group Ltd.